Tango Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for TNGX, updated each market day.
TNGX AI Sentiment
AI predicts Tango Therapeutics, Inc. stock is likely to decrease over the next 10 market days.
Prediction date: Sept. 16, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Tango Therapeutics, Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Sector
Exchange
Market Cap
$3,940,424,276
Cap Tier
Employees
137
Headquarters
BOSTON, MA
Listed Since
Aug. 11, 2021
Website
TNGX Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TNGX Volatility
Tango Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
